Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Vical
July 28, 2014
Therapeutic focus – Herpes treatment turns to immune approach
April 30, 2014
EP Vantage Interview – Newly public UniQure looks to Glybera launch and pipeline
February 26, 2014
Therapeutic focus – Gene therapy slowly rises from the ashes
August 13, 2013
Unequivocal failure sees Vical ditch gene therapy
February 14, 2013
Ten oncology companies to avoid
July 20, 2012
Key data readouts in the second half of 2012
April 05, 2012
Vivus, Amylin and Threshold notable small cap gainers in Q1
February 16, 2012
Therapeutic focus – HIV vaccines space needs injection of enthusiasm
January 06, 2012
Small caps produce clear winners and losers in 2011
November 17, 2011
AHA 2011 - Positive data puts stem cells in spotlight
August 25, 2011
Most valuable unpartnered pipeline assets – what's hot and what's not
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
April 22, 2021
Evaluate Vantage Report: US Approvals Under the Spotlight
February 11, 2021
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
Editor's Picks
March 22, 2021
AACR 2021 preview – the early themes emerge
March 24, 2021
Big pharma’s key catalysts in the second quarter
March 03, 2021
A busy year ahead for Parkinson’s disease
March 23, 2021
Frequency refuses to hear the death knell
February 18, 2021
The reckoning begins for biotech-focused Spacs
